Lenzetto

Estradiol, the active ingredient in Lenzetto, is an estrogen presented as a transdermal patch for transdermal use. It provides hormone replacement therapy to alleviate menopausal vasomotor symptoms and to prevent postmenopausal osteoporosis in women.

GNH USA supplies Lenzetto as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lenzetto delivers estradiol to target estrogen‑dependent pathways, addressing several menopause‑related conditions.

Menopausal vasomotor symptoms: reduces hot flashes and night sweats in postmenopausal women. Postmenopausal osteoporosis: helps maintain bone mineral density and lowers fracture risk. Hypoestrogenism due to ovarian failure or hypogonadism: restores estrogen levels in women with low endogenous production.

Transdermal estradiol may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Skin irritation at the patch site: redness, itching or rash. - Headache: mild to moderate intensity. - Breast tenderness: discomfort or swelling. - Nausea: occasional upset stomach. - Mood changes: irritability or mild depression. - Bloating: abdominal fullness.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Stroke or transient ischemic attack. - Myocardial infarction: heart attack risk. - Gallbladder disease: cholecystitis or gallstones. - Hepatic dysfunction: abnormal liver enzymes. - Endometrial hyperplasia or cancer: especially if unopposed by progestogen.

Before prescribing Lenzetto, clinicians should evaluate several safety considerations.

Assess cardiovascular risk: review history of thromboembolism, stroke or myocardial infarction. Screen for estrogen‑sensitive cancers: avoid in active breast or endometrial cancer. Monitor liver function: adjust use in patients with hepatic impairment. Consider bone health: incorporate into comprehensive osteoporosis management. Avoid use during pregnancy: contraindicated in pregnant women. Store at room temperature below 25°C: keep in the original pouch, protect from moisture and direct sunlight.

Estradiol can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Combined estrogen‑containing oral contraceptives: increased risk of thromboembolic events. - Anticoagulants (e.g., warfarin): potential enhancement of anticoagulant effect. - Selective estrogen receptor modulators (e.g., tamoxifen): antagonistic pharmacodynamic interaction.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (rifampin, carbamazepine): may reduce estradiol plasma levels. - CYP3A4 inhibitors (ketoconazole, erythromycin): may increase estradiol exposure. - Thyroid hormone replacement therapy: may require dose adjustment of levothyroxine.